Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

One example of an emerging candidate under review is Regeneron’s Linvoseltamab, an investigational, fully human, BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA ...

The body then produces antibodies that can fight the coronavirus. Regeneron’s name might indicate that it’s a pharmaceutical company. However, Regeneron actually meets the definition of a ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Regeneron beats quarterly estimates on eczema ... 2024 US FDA revokes authorization for four COVID antibody drugs The U.S. Food and Drug Administration has revoked the emergency use authorization ...